ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Personalizing treatment of pancreatitis-associated chronic pain: the need for an integrated omics approach.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundChronic pancreatitis (CP) is a progressive inflammatory disorder characterized by debilitating chronic pain and substantial healthcare burden. Pain mechanisms in CP are heterogeneous and incompletely integrated into clinical decision-making. This narrative review synthesizes data from human CP cohorts and complementary experimental models to summarize inflammatory, neuropathic, and metabolic drivers of pancreatitis-associated pain and to evaluate how integrated multi-omics approaches may enable mechanism-based precision management. Current treatment relies on lifestyle modification, anatomy-guided interventions, stepwise pharmacologic escalation, and surgery for refractory cases. Emerging ion-channel-targeted therapies show promise, but inconsistent patient selection and limited biomarker guidance constrain therapeutic precision.
findingsCP-associated pain arises from convergent inflammatory, neuroimmune, neuropathic, and metabolic pathways that promote peripheral and central sensitization with sustained neuroplastic remodeling. Advances in clinical phenotyping have improved characterization of pain subtypes; however, integration of biologic data remains limited. Genetic association studies increasingly implicate pathways linked to severe or persistent pain phenotypes. Omics investigations have identified candidate genomic, proteomic, and metabolomic signals that may support biologically informed stratification and treatment prediction. Nevertheless, most studies are cross-sectional, modality-specific, and derived from heterogeneous cohorts with inconsistent endpoints and limited external validation.
conclusionsIntegration of rigorous clinical phenotyping with longitudinal, multi-omics modeling provides a framework for developing testable, mechanism-based biomarkers to guide personalized analgesic and procedural strategies while supporting opioid-sparing care. Priorities include harmonization of multicenter datasets, standardized and longitudinal pain outcome measurement, expanded paired biospecimen collection, and external validation of predictive models. Such efforts may enable biologically grounded pain stratification and facilitate translation of biomarker-guided decision tools into routine clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.